Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

Drugmakers have been warned that the Trump Administration is considering linking U.S. medicine prices to lower amounts paid ...

CompanyOverview|NYSE:MDT] Investors increasingly seek stable and resilient investments in today's volatile and economically ...

Westbury’s school district is continuing its tradition of leveraging lawsuits to advocate for the school’s community.

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...